Nordic Nanovector

Activities: Research & Development

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Finance

Nordic Nanovector to explore strategic options

Nordic Nanovector announces that its Board of Directors has appointed Carnegie Investment Bank to explore strategic options available to the company
Finance

Nordic Nanovector appoints Peter Braun CEO

In addition to his experience at Roche, Braun has also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies
Regulatory

Nordic Nanovector appoints Dr Reza Safaei as head of Medical Affairs

Nordic Nanovector appoints Lisa Rojkjaer, MD as Chief Medical Officer

Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team.
Ingredients

Nordic Nanovector and Heidelberg Pharma collaborate to develop novel ADCs targeting leukaemias

Leukaemias are orphan diseases with a significant unmet medical need, applicable indications representing a growing market worth more than $5 billion by 2020
Ingredients

Nordic Nanovector and LegoChem Biosciences collaborate to develop novel antibody-drug conjugates (ADCs) targeting leukaemias

Leukemias are orphan diseases with a significant unmet medical need, representing a growing market estimated to be worth more than $5 billion by 2024
Regulatory

Betalutin publications highlight benefits of predosing regimen

Lilotomab predosing of NHL patients before Betalutin therapy lowers haematological toxicity with no reduction in the tumour absorbed radiation dose
Subscribe now